CSIMarket



Beam Therapeutics Inc   (BEAM)
Other Ticker:  
 
 

BEAM's Capital Expenditures Growth by Quarter and Year

Beam Therapeutics Inc 's Capital Expenditures results by quarter and year




BEAM Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 13.37 8.13 -128.50
III Quarter September - 5.78 2.82 -
II Quarter June - 16.18 2.37 30.90
I Quarter March 7.26 11.48 3.05 31.00
FY   7.26 46.81 16.37 -66.60



BEAM Capital Expenditures first quarter 2022 Y/Y Growth Comment
Beam Therapeutics Inc reported fall in Capital Expenditures in the first quarter 2022 by -36.77% to $ 7.26 millions, from the same quarter in 2021.
The drop in the first quarter 2022 Beam Therapeutics Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures growth of 9.87%.

Looking into first quarter 2022 results within Biotechnology & Pharmaceuticals industry 65 other companies have achieved higher Capital Expenditures growth. While Beam Therapeutics Inc ' s Capital Expenditures drop of -36.77% ranks overall at the positon no. 2094 in the first quarter 2022.




BEAM Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - 64.45 % - -
III Quarter September - 104.96 % - -
II Quarter June - 582.7 % -92.33 % -1.28 %
I Quarter March -36.77 % 276.39 % -90.16 % -11.17 %
FY   - 185.95 % - -

Financial Statements
Beam Therapeutics Inc 's first quarter 2022 Capital Expenditures $ 7.26 millions BEAM's Income Statement
Beam Therapeutics Inc 's first quarter 2021 Capital Expenditures $ 11.48 millions Quarterly BEAM's Income Statement
New: More BEAM's historic Capital Expenditures Growth >>


BEAM Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - 131.31 % 188.3 % -
III Quarter September - -64.28 % 18.99 % -
II Quarter June - 40.94 % -22.3 % -0.32 %
I Quarter March -45.71 % 41.21 % - -
FY (Year on Year)   - 185.95 % - -




Capital Expenditures first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #66
Healthcare Sector #330
Overall #2094

Capital Expenditures Y/Y Growth Statistics
High Average Low
130.12 % 9.87 % -50.16 %
(June 30. 2011)   (March 31, 2013)
Capital Expenditures first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #66
Healthcare Sector #330
Overall #2094
Capital Expenditures Y/Y Growth Statistics
High Average Low
130.12 % 9.87 % -50.16 %
(June 30. 2011)   (March 31, 2013)

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Beam Therapeutics Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
188.22 % 14.32 % -100 %
(Dec 31 2020)  


BEAM's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2022 Beam Therapeutics Inc disclosed fall in Capital Expenditures from the previous quarter by -45.71% to $ 7.26 millions, from $ 13.37 millions declared in the previous reporting period.

Even periodic factors which usually energize I. Quarter 2022 Capital Expenditures, were not able to salvage the I. Quarter for the Beam Therapeutics Inc , Sebastian  Robinson, an industry insider wrote, he sees new headwinds onward for the Biotechnology & Pharmaceuticals's company and wrote that average sequential Capital Expenditures growth is at 14.32% for the Biotechnology & Pharmaceuticals's company.

Within Biotechnology & Pharmaceuticals industry 80 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Beam Therapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1974.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #81
Healthcare Sector #348
Overall #1974
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #81
Healthcare Sector #348
Overall #1974
Capital Expenditures Q/Q Growth Statistics
High Average Low
188.22 % 14.32 % -100 %
(Dec 31 2020)  


BEAM's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2022 Beam Therapeutics Inc reported fall in Capital Expenditures from the forth quarter by -45.71% to $ 7.26 millions, from $ 13.37 millions achived in the previous quarter.

Even cyclical circumstance which normally fuel I. Quarter 2022 results, it clearly could not be sufficient to salvage BEAM's I. Quarter 2022 achievement, Sebastian  Robinson, an industry insider wrote and continued that average sequential Capital Expenditures growth is at 14.32% for Beam Therapeutics Inc .

Within Biotechnology & Pharmaceuticals industry 80 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Beam Therapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 1974.


Beam Therapeutics Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Capital Expenditures 12 Months Ending $ 42.59 $ 46.81 $ 41.57 $ 38.61 $ 24.79
Y / Y Capital Expenditures Growth (TTM) 71.82 % 186.18 % - - -
Year on Year Capital Expenditures Growth Overall Ranking # 629 # 351 # 0 # 0 # 603
Seqeuential Capital Expenditures Change (TTM) -9.01 % 12.62 % 7.67 % 55.74 % 51.55 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 2094 # 1195 # 1044 # 302 # 2025




Cumulative Capital Expenditures growth Comment
Assuming the Beam Therapeutics Inc 's fiscal year would have ended in Mar 31 2022, Beam Therapeutics Inc would have reprted above average annual Capital Expenditures growth of 71.82% year on year, of $ 43 millions.
This marks a slow-down of the companys growth trends and from the 186.18% surge in Dec 31 2021.

In the Healthcare sector 122 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 351 to 629.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
130.12 %
9.87 %
-50.16 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 66
Healthcare Sector # 123
Overall # 629

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
186.18 %
14.26 %
-72.59 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 66
Sector # 330
S&P 500 # 2094
Cumulative Capital Expenditures growth Comment
Assuming the Beam Therapeutics Inc 's fiscal year would have ended in Mar 31 2022, Beam Therapeutics Inc would have reprted above average annual Capital Expenditures growth of 71.82% year on year, of $ 43 millions.
This marks a slow-down of the companys growth trends and from the 186.18% surge in Dec 31 2021.

In the Healthcare sector 122 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 351 to 629.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
130.12 %
9.87 %
-50.16 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 66
Healthcare Sector # 123
Overall # 629

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
186.18 %
14.26 %
-72.59 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 66
Sector # 330
S&P 500 # 2094




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
BEAM's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for BEAM's Competitors
Capital Expenditures Growth for Beam Therapeutics Inc 's Suppliers
Capital Expenditures Growth for BEAM's Customers

You may also want to know
BEAM's Annual Growth Rates BEAM's Profitability Ratios BEAM's Asset Turnover Ratio BEAM's Dividend Growth
BEAM's Roe BEAM's Valuation Ratios BEAM's Financial Strength Ratios BEAM's Dividend Payout Ratio
BEAM's Roa BEAM's Inventory Turnover Ratio BEAM's Growth Rates BEAM's Dividend Comparisons



Companies with similar Capital Expenditures surge for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Mar 31 2022
Brookdale Senior Living Inc -1.00%$ -1.003 millions
Alkermes Plc -2.44%$ -2.442 millions
Novabay Pharmaceuticals Inc -4.00%$ -4.000 millions
Shattuck Labs Inc -5.69%$ -5.686 millions
Morphic Holding inc -5.88%$ -5.882 millions
Fulcrum Therapeutics Inc -6.11%$ -6.107 millions
Vbi Vaccines Inc-7.37%$ -7.374 millions
Community Health Systems Inc -7.62%$ -7.619 millions
Sqz Biotechnologies Company-7.69%$ -7.692 millions
Tarsus Pharmaceuticals Inc -8.00%$ -8.000 millions
Inspire Medical Systems inc -8.02%$ -8.024 millions
Becton Dickinson And Company-10.28%$ -10.277 millions
Vertex Pharmaceuticals Inc-10.33%$ -10.329 millions
Xtant Medical Holdings Inc -10.70%$ -10.701 millions
Myriad Genetics Inc -11.27%$ -11.268 millions
Exact Sciences Corporation-11.33%$ -11.332 millions
Inogen Inc -11.41%$ -11.414 millions
Alphatec Holdings Inc -11.81%$ -11.808 millions
Avanos Medical Inc -12.28%$ -12.281 millions
Merck and Co Inc -13.23%$ -13.228 millions
Genocea Biosciences Inc -13.35%$ -13.345 millions
Abbvie Inc -13.83%$ -13.830 millions
Acadia Healthcare Company Inc -13.90%$ -13.897 millions
Procyon Corp-14.32%$ -14.319 millions
Ocugen Inc -14.56%$ -14.559 millions
Davita Inc -15.05%$ -15.047 millions
Biolife Solutions Inc-15.35%$ -15.349 millions
Covetrus Inc -15.38%$ -15.385 millions
Bausch Health Companies Inc -16.18%$ -16.176 millions
Pactiv Evergreen Inc -16.67%$ -16.667 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

RESI's Profile

Stock Price

RESI's Financials

Business Description

Fundamentals

Charts & Quotes

RESI's News

Suppliers

RESI's Competitors

Customers & Markets

Economic Indicators

RESI's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071